Holen Sie sich die Stockscreener-App
1.16
4.13%
-0.05
Handel nachbörslich:
1.14
-0.02
-1.72%
Schlusskurs vom Vortag:
$1.21
Offen:
$1.2
24-Stunden-Volumen:
73,584
Relative Volume:
0.08
Marktkapitalisierung:
$5.59M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-6.78M
KGV:
-0.0272
EPS:
-42.6996
Netto-Cashflow:
$-4.67M
1W Leistung:
-6.83%
1M Leistung:
-17.73%
6M Leistung:
-5.69%
1J Leistung:
-27.04%
1-Tages-Spanne:
$1.14
$1.28
1-Wochen-Bereich:
$1.14
$1.29
52-Wochen-Spanne:
$0.9512
$2.30
Clearmind Medicine Inc Stock (CMND) Company Profile
Firmenname
Clearmind Medicine Inc
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie CMND mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CMND
Clearmind Medicine Inc
|
1.16 | 5.59M | 0 | -6.78M | -4.67M | -42.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.31 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
684.87 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
622.61 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.53 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
111.56 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Clearmind Medicine Inc Aktie (CMND) Neueste Nachrichten
SciSparc Ltd. announced that it expects to receive $2 million in funding from Yorkville Advisors Global LP - Marketscreener.com
Head-To-Head Comparison: Clearmind Medicine (CMND) versus The Competition - Defense World
Clearmind Medicine (NASDAQ:CMND) Stock Quotes, Forecast and News Summary - Benzinga
SciSparc-Clearmind Collaboration Leads to Publication of Patent for Binge Behaviour Combination Treatment in Mexico - GlobeNewswire
SciSparc and Clearmind’s Patent Publication Marks Progress in Binge Behavior Treatment - TipRanks
Clearmind Medicine Secures Patent For Psychedelic Combination Therapy In Mexico - Nasdaq
SciSparc Ltd.-Clearmind Collaboration Leads to Publication of Patent for Binge Behaviour Combination Treatment in Mexico - Marketscreener.com
SciSparc Ltd. and Clearmind Medicine Inc. Collaborate on Patent Application for Innovative Combination Therapy to Address Binge Behaviors - Nasdaq
Game-Changing Addiction Treatment Patent: SciSparc-Clearmind's MDMA Breakthrough Expands Global Reach - StockTitan
Clearmind Medicine Announces Publication of Patent for Binge Behavior Psychedelic Combination Treatment in Mexico - The Manila Times
Clearmind Medicine Inc. Announces Patent Publication for Innovative Combination Therapy Targeting Binge Behavior - Nasdaq
Novel Psychedelic-Based Therapy Gets Patent Green Light: Targets Multiple Addictions - StockTitan
EXCLUSIVE: Psychedelic-Focused Firm Clearmind Medicine Submits Three New International Patent Applications For MDMA, Ibogaine And Ketamine Compounds - MSN
SciSparc Ltd. Delivers Treatment for Autism Spectrum Disorder Clinical Trial Enabling Commencement of Dosing - Marketscreener.com
Clearmind Medicine (NASDAQ:CMND) Trading Up 6.3% – Still a Buy? - Defense World
SciSparc Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 - Marketscreener.com
Clearmind Medicine Announces Shareholders Meeting Results - The Manila Times
Scisparc-Clearmind Medicine Collaboration Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment - Marketscreener.com
SciSparc and Clearmind Medicine Advance with European Patent Application for Psychedelic Binge Behavior Treatment - TipRanks
Clearmind Medicine files European patent for binge behavior therapy By Investing.com - Investing.com Nigeria
Why Is Psychedelic-SciSparc Stock Trading Higher On Monday? - AOL
Clearmind Medicine Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment - Marketscreener.com
Clearmind Medicine files European patent for binge behavior therapy - Investing.com
Lexitas Elevates Nishat Mehta to CEO, Prepares to Launch AI-Assisted Solutions for the Legal Profession Throughout 2025 - The Manila Times
SciSparc-Clearmind Medicine Collaboration Announces the - GlobeNewswire
SciSparc and Clearmind Secure European Patent for Groundbreaking Binge Behavior Treatment - StockTitan
Pharma Stock SciSparc Ltd. (Nasdaq: SPRC) Soars on Psychedelic News - Investorideas.com newswire
Clearmind Medicine Granted Patent for Binge Behavior Treatment by the Macau International Intellectual Property Office - The Manila Times
Clearmind Medicine Granted Patent for Binge Behavior Treatment by the Macau International Intellectual Property Office - GlobeNewswire Inc.
Scisparc Ltd. Announces Initiation of Patient Recruitment for Its Clinical Trial with Sci-210 in Children with Autism Spectrum Disorder - Marketscreener.com
Clearmind Medicine to move forward with MEAI-based alcohol substitute - Yahoo Finance
Clearmind Medicine Looks to Move Forward with its Novel Psychedelic MEAI- Based Alcohol Substitute - EIN News
Clearmind Medicine Partners with Dr Glitter to Develop Crystal-Based Alcohol Alternative - StockTitan
Clearmind Medicine receives IRB approval for Phase I/IIa clinical trial of CMND-100 - MSN
Clearmind Medicine advances in AUD treatment trial By Investing.com - Investing.com South Africa
SciSparc Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024 - Marketscreener.com
Scisparc Ltd. with Clearmind Medicine Inc. Publishes for the Innovative Combination of 3,4-Methylenedioxymethamphetamine with N-Acylethanolamines - Marketscreener.com
Clearmind Medicine Inc. Receives IRB Approval for its FDA-Regulated Clinical Trial - Marketscreener.com
SciSparc Ltd. Announces Finalize an Exclusive Patent License Agreement with Polyrizon Ltd - Marketscreener.com
Clearmind Medicine Inc. Announces Publication of International Patent Application for Innovative MDMA-Based Combination Treatment - Marketscreener.com
Scisparc Ltd. and Clearmind Medicine Collaboration Announces the Publication of an International Patent Application for Pioneering Ibogaine Combination Therapy - Marketscreener.com
SciSparc Ltd. Announces U.S. Patent Application for Treating Metabolic Syndrome and Weight Loss - Marketscreener.com
BeyondSpring (BYSI) Stock Drops Amidst Biotech Sector Volatility - GuruFocus.com
Why Is Penny Stock Clearmind Gaining Today? - Benzinga
Regulatory Approval Sends Clearmind Medicine (CMND) Soaring Pre-Market - Stocks Telegraph
Clearmind Medicine Shares Double on Trial Approval - MarketWatch
Clearmind Medicine advances in AUD treatment trial - Investing.com
Clearmind Medicine Receives IRB Approval for its FDA-Regulated Clinical Trial - The Manila Times
Clearmind Medicine (NASDAQ:CMND) Shares Up 3.5% – Time to Buy? - Defense World
Clearmind Medicine and Dr Glitter Pty Ltd Sign Term Sheet for Mutual Development of Novel Psychedelic MEAI- Based Alcohol Substitute in ActivCrystal™ Format - The Manila Times
Clearmind Medicine and Dr Glitter Pty Ltd Sign Term Sheet for Mutual Development of Novel Psychedelic MEAI-Based Alcohol Substitute in ActivCrystal? Format - Marketscreener.com
Finanzdaten der Clearmind Medicine Inc-Aktie (CMND)
Umsatz
Nettogewinn
Free Cashflow
ENV
6.45%
1.23%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):